CJC-1295
Also known as: CJC-1295 DAC · CJC-1295 No DAC · Modified GRF 1-29
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates sustained, pulsatile GH release from the pituitary gland.
Overview
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) consisting of 29 amino acids. It was developed to provide a longer-lasting stimulation of growth hormone release compared to natural GHRH. The peptide exists in two forms: with DAC (Drug Affinity Complex) which extends its half-life to approximately 6-8 days by binding to albumin, and without DAC (also known as Modified GRF 1-29) which has a shorter half-life of about 30 minutes. The no-DAC version is generally preferred in health optimization circles because it produces a more natural, pulsatile release pattern of growth hormone rather than a sustained elevation, which more closely mimics the body's natural GH secretion rhythm.
CJC-1295 works by binding to GHRH receptors on somatotroph cells in the anterior pituitary, triggering the synthesis and secretion of growth hormone. Unlike exogenous HGH administration, CJC-1295 preserves the body's natural feedback mechanisms, reducing the risk of GH receptor desensitization.
Mechanism of Action
Binds to GHRH receptors on pituitary somatotroph cells, stimulating cAMP-mediated signaling cascades that increase GH gene transcription and secretion. The DAC version binds to serum albumin via a reactive succinimidyl ester, extending plasma half-life significantly.
Key Benefits
Potential Side Effects
Common Stacks
This peptide is commonly combined with the following compounds for synergistic effects:
Known Interactions
The following interactions have been documented for CJC-1295. Always consult a healthcare professional before combining compounds.
Use Caution (2)
Both are GHRH analogs competing for the same receptor. Using together provides diminishing returns and may desensitize GHRH receptors faster.
IGF-1 LR3 provides exogenous IGF-1 while CJC-1295 stimulates endogenous GH/IGF-1. Combined use may result in excessive IGF-1 levels.
Synergistic (3)
Classic GH stack — CJC-1295 provides sustained GHRH signaling while Ipamorelin triggers acute GH pulses via the ghrelin receptor. Together they amplify GH release beyond either alone.
CJC-1295 (GHRH analog) combined with MK-677 (oral ghrelin mimetic) provides dual-pathway GH stimulation with the convenience of oral + injectable dosing.
Hexarelin (GHRP) paired with CJC-1295 (GHRH) provides robust GH release. Note: Hexarelin may elevate cortisol and prolactin more than Ipamorelin.
Scientific References
Quick Reference
Typical Dose
100-300 mcg
Frequency
1-2 times daily (No DAC) or 2x/week (with DAC)
Route
Subcutaneous injection
Half-Life
~30 min (No DAC) / 6-8 days (with DAC)
Cycle Length
12-16 weeks on, 4-8 weeks off
FDA Status
Not FDA approved; research chemical
Need to calculate dosing?
Use our reconstitution calculator to determine exact syringe measurements.
Open CalculatorThis information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.
Related Peptides in Growth Hormone Secretagogues
Ipamorelin
A highly selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol, prolactin, or appetite.
Read moreSermorelin
A bioidentical GHRH analog representing the first 29 amino acids of natural GHRH, providing the most physiologically natural approach to GH stimulation.
Read moreMK-677
An orally active, non-peptide growth hormone secretagogue that mimics ghrelin signaling to produce sustained elevations in GH and IGF-1.
Read more